Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Thoracic Surgery

Free Subscription Articles published in Am Heart J Retrieve available abstracts of 125 articles: HTML format

Single Articles

November 2026
1. FANG J, Ma Y, Chen Y, Lai Y, et al
   Rationale and design of the TAILOR-HCM multicenter randomized controlled trial: Transapical beating-heart septal myectomy for obstructive hypertrophic cardiomyopathy.
   Am Heart J. 2026;301:107543.
   PubMed     Abstract available
   
   
   
2. GAUDINO M, Stone GW, Puskas J, Krieger K, et al
   Lessons learned from the feasibility phase of the REvascularization CHoices Among Under-Represented Groups Evaluation (RECHARGE) trial program.
   Am Heart J. 2026;301:107515.
   PubMed     Abstract available
   
   
   October 2026
3. D'ASCENZO F, De Filippo O, Pelliccia F, Pasceri V, et al
   Potentially futile outcome after uncomplicated TAVI: Insights from the TRITAVI registry.
   Am Heart J. 2026;300:107488.
   PubMed     Abstract available
   
   
   
4. BROYD CJ, Arunothayaraj S, Scheller B, Eccleshall S, et al
   The European bifurcation club randomized trial of stepwise provisional stenting vs drug-coated balloon therapy for nonleft main true coronary bifurcations: The EBC DCB trial.
   Am Heart J. 2026;300:107463.
   PubMed     Abstract available
   
   
   July 2026
5. OPOLSKI MP, Spiewak M, Machaj F, Borzuta H, et al
   Antegrade dissection and re-entry versus retrograde strategy in chronic total occlusion percutaneous coronary intervention: Rationale and design of the ADRENALINE randomized study.
   Am Heart J. 2026 Jul 11:107538. doi: 10.1016/j.ahj.2026.107538.
   PubMed     Abstract available
   
   
   
6. AROW Z, Oliva O, Seyeddi SS, Bonfils L, et al
   Assessment of the gradient gap after TAVR with balloon and self-expandable valves: Analysis of a large patient cohort.
   Am Heart J. 2026;297:107428.
   PubMed     Abstract available
   
   
   June 2026
7. MURO FMD, Raona V, Sartori S, Smith K, et al
   Prognostic Impact of Combined Inflammatory Markers in Patients Undergoing Percutaneous Coronary Intervention.
   Am Heart J. 2026 Jun 21:107519. doi: 10.1016/j.ahj.2026.107519.
   PubMed     Abstract available
   
   
   
8. LIP GYH, Kuzma L
   Revisiting Direct Oral Anticoagulant Monotherapy Versus Combination Therapy With Antiplatelets In Chronic Coronary Syndrome Patients With Prior Percutaneous Coronary Intervention: Balancing thromboembolism, mortality and bleeding.
   Am Heart J. 2026 Jun 8:107509. doi: 10.1016/j.ahj.2026.107509.
   PubMed    
   
   
   
9. SHEASHAA H, Farina JM, Awad K, Abbas MT, et al
   Clinical Outcomes and Impact of Aortic Valve Replacement in Concordant vs. Discordant High-Gradient Aortic Stenosis.
   Am Heart J. 2026 Jun 5:107507. doi: 10.1016/j.ahj.2026.107507.
   PubMed     Abstract available
   
   
   
10. CORTESE B, Mohammed AA, Malakouti S, Sivalingam J, et al
    Antiplatelet treatment after drug-coated balloon treatment: Review of the current evidence and future perspectives.
    Am Heart J. 2026;296:107361.
    PubMed     Abstract available
    
    
    
11. LIAO W, Rashid M, Brookes CL, Barber S, et al
    Study design for an emulated trial of a 2 arm, parallel, stratified, adaptive, RCT of CABG versus PCI in people requiring myocardial revascularization at high risk (High-Risk REVASC).
    Am Heart J. 2026;296:107368.
    PubMed     Abstract available
    
    
    May 2026
12. GOUDA P MB BCH BAO, Cyr DD, Chiswell K, Mercer J, et al
    Evaluation, Treatment, and Outcomes in Patients With Possible Severe Aortic Stenosis.
    Am Heart J. 2026 May 30:107498. doi: 10.1016/j.ahj.2026.107498.
    PubMed     Abstract available
    
    
    
13. COSTA G, Laterra G, Sammartino S, De Backer O, et al
    Progression of bicuspid-related aortopathy in patients undergoing Transcatheter Aortic Valve Implantation: rationale and design of the international, multicenter PROSPERO-TAVI registry.
    Am Heart J. 2026 May 27:107494. doi: 10.1016/j.ahj.2026.107494.
    PubMed     Abstract available
    
    
    
14. TOMII D, Lanz J, Heg D, Thiele H, et al
    Relationship between baseline patient-reported health status and patient-centered outcomes after Transcatheter Aortic Valve Replacement.
    Am Heart J. 2026 May 26:107495. doi: 10.1016/j.ahj.2026.107495.
    PubMed     Abstract available
    
    
    
15. CHI KY, Karthikeyan A, Chang Y, Lee PL, et al
    Direct Oral Anticoagulant Monotherapy versus Combination Therapy with Antiplatelets in Chronic Coronary Syndrome Patients with Prior Percutaneous Coronary Intervention Requiring Anticoagulation: A Meta-Analysis.
    Am Heart J. 2026 May 17:107492. doi: 10.1016/j.ahj.2026.107492.
    PubMed     Abstract available
    
    
    April 2026
16. WOELDERS ECI, Yosofi B, Peeters DAM, von Birgelen C, et al
    Short-term outcomes of ticagrelor monotherapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction; a randomized pilot study.
    Am Heart J. 2026 Apr 28:107460. doi: 10.1016/j.ahj.2026.107460.
    PubMed     Abstract available
    
    
    
17. JANSSEN S, Luijkx JJP, Swinnen W, Vriesendorp P, et al
    Direct oral anticoagulation interruption versus continuation in patients undergoing elective invasive coronary angiography or percutaneous coronary intervention: design and rationale of the South Limburg Myocardial Infarction study group trial 2 (SLIM
    Am Heart J. 2026 Apr 27:107462. doi: 10.1016/j.ahj.2026.107462.
    PubMed     Abstract available
    
    
    
18. ELBENAWI H, Hassan I, Abdelgalil MS, Hanna M, et al
    Cerebral Embolic Protection Devices for Transcatheter Aortic Valve Replacement: A Meta-Analysis and Trial Sequential Analysis.
    Am Heart J. 2026 Apr 24:107449. doi: 10.1016/j.ahj.2026.107449.
    PubMed     Abstract available
    
    
    March 2026
19. SORENSEN LM, Reinert MS, Raja AA, de Backer O, et al
    Design and rationale of the EMPagliflozin after Aortic Valve Replacement (EMPAVR) study: a randomized clinical trial.
    Am Heart J. 2026 Mar 26:107432. doi: 10.1016/j.ahj.2026.107432.
    PubMed     Abstract available
    
    
    
20. GOLDSTEIN DJ, Reichenspurner H, Vorovich E, Teuteberg J, et al
    Design and Rationale of the Impella(R)-Protected Cardiac Surgery Trial (IMPACT): A Multicenter, Single-arm Pilot Study in High-Risk Cardiac Surgery Patients.
    Am Heart J. 2026 Mar 25:107434. doi: 10.1016/j.ahj.2026.107434.
    PubMed     Abstract available
    
    
    
21. GENEREUX P, Makkar RR, Bax JJ, Pibarot P, et al
    Design and rationale of the prospective, randomized, controlled trial to assess the management of moderate aortic stenosis by clinical surveillance or transcatheter aortic valve replacement: The PROGRESS Trial.
    Am Heart J. 2026;297:107433.
    PubMed     Abstract available
    
    
    
22. IRIBARREN C, Lu M, Go AS, Rana JS, et al
    Attaining LDL-cholesterol target post major coronary event: Care gap, associated factors and clinical outcomes.
    Am Heart J. 2026 Mar 21:107430. doi: 10.1016/j.ahj.2026.107430.
    PubMed     Abstract available
    
    
    
23. POLETTI E, Thotakura S, Kearney KE, Lombardi WL, et al
    Comparative Validation of Risk Scores for In-Hospital Complications Following Chronic Total Occlusion Percutaneous Coronary Intervention.
    Am Heart J. 2026 Mar 19:107427. doi: 10.1016/j.ahj.2026.107427.
    PubMed     Abstract available
    
    
    
24. DIMAGLI A, Redfors B, Gaudino M
    Trial Event Rate Assumption and Noninferiority Margin in Comparative Trials of Aortic Valve Replacement.
    Am Heart J. 2026 Mar 17:107425. doi: 10.1016/j.ahj.2026.107425.
    PubMed     Abstract available
    
    
    
25. PAUSCH J, Bhadra O, Weimann J, Hua X, et al
    Evolution of endoscopic mitral valve surgery over a 11-year period at a high-volume center.
    Am Heart J. 2026 Mar 17:107424. doi: 10.1016/j.ahj.2026.107424.
    PubMed     Abstract available
    
    
    February 2026
26. THIM T, Nissen H, Niemela M, Eftekhari A, et al
    Design and rationale of the COMPARE-TAVI 2 trial: An all-comers head-to-head comparison of Evolut FX+ and Sapien 3 Ultra Resilia transcatheter heart valves.
    Am Heart J. 2026 Feb 23:107387. doi: 10.1016/j.ahj.2026.107387.
    PubMed     Abstract available
    
    
    
27. HEUTS S, Pustjens TFS, Lux A, Gabrio A, et al
    Probabilities of treatment effects in complete or culprit-only revascularization for NSTEMI: a Bayesian re-analysis of the SLIM trial.
    Am Heart J. 2026 Feb 5:107369. doi: 10.1016/j.ahj.2026.107369.
    PubMed     Abstract available
    
    
    
28. HILL KD, Koerner J, Hong H, Li JS, et al
    A Bayesian re-analysis of the STRESS trial.
    Am Heart J. 2026;292:107282.
    PubMed     Abstract available
    
    
    January 2026
29. ARMSTRONG PW, Zheng Y, Welsh RC, Sinnaeve PR, et al
    Primary Percutaneous Coronary Intervention within the First Hour: Insights from Early-Treated Patients with ST-Elevation Myocardial Infarction.
    Am Heart J. 2026 Jan 29:107363. doi: 10.1016/j.ahj.2026.107363.
    PubMed     Abstract available
    
    
    
30. WANG C, Liu Z, Li Z, Yan X, et al
    STrategies for Antithrombotic tRreatment following Transcatheter Edge-to-Edge Repair in patients with severe mitral regurgitation: rationale and design of STAR-TEER trial.
    Am Heart J. 2026 Jan 28:107362. doi: 10.1016/j.ahj.2026.107362.
    PubMed     Abstract available
    
    
    
31. VEKSTEIN AM, Salah HM, Stebbins A, Wegermann Z, et al
    Early Outcomes of Off-Label Transcatheter Tricuspid Valve Repair/Replacement in the STS/ACC TVT Registry.
    Am Heart J. 2026 Jan 19:107355. doi: 10.1016/j.ahj.2026.107355.
    PubMed     Abstract available
    
    
    
32. MAYOURIAN J, Sleeper LA, Diwanji V, Geva A, et al
    Artificial intelligence-enabled electrocardiogram guidance for pulmonary valve replacement timing in repaired tetralogy of Fallot.
    Am Heart J. 2026;291:153-161.
    PubMed     Abstract available
    
    
    
33. SHAH AH, Armstrong HK, Mittal I, Reimer A, et al
    IMpact of therapY using coleSevelam treatment reducing bile acids in patients with fonTan cIrCulation (MYSTIC): Rationale and study design.
    Am Heart J. 2026;291:81-88.
    PubMed     Abstract available
    
    
    December 2025
34. D'ENTREMONT MA, Lee SF, Wijeysundera HC, Tsang MB, et al
    Design and Rationale of the HD PCI Trial: A Cluster Randomized Crossover Trial of Higher vs. Lower Dose Heparin for Elective Percutaneous Coronary Intervention.
    Am Heart J. 2025 Dec 22:107330. doi: 10.1016/j.ahj.2025.107330.
    PubMed     Abstract available
    
    
    
35. HARVEY JE 3RD, Ryan M, Gunnarsson C, Chikermane S, et al
    Incremental cost of complications after TAVR and SAVR in contemporary clinical practice.
    Am Heart J. 2025;290:278-287.
    PubMed     Abstract available
    
    
    
36. ALSAIED T, Li R, Grant H, Schiff MD, et al
    Defining diastolic dysfunction post-Fontan: Threshold, risk factors, and associations with outcomes.
    Am Heart J. 2025;290:288-296.
    PubMed     Abstract available
    
    
    
37. ABDELHALIM AT, Reddy YVN, Miranda WR, Kamath PS, et al
    Prognostic value of liver biomarker scores for risk stratification in adults with Fontan palliation.
    Am Heart J. 2025;290:170-179.
    PubMed     Abstract available
    
    
    
38. LI Y, Schiff M, Olivieri LJ, Christopher AB, et al
    The long-term effect of the Fontan fenestration on clinical outcomes: A FORCE registry study.
    Am Heart J. 2025;290:105-114.
    PubMed     Abstract available
    
    
    
39. GALLEGOS FN, Bernstein D, Punn R, Long J, et al
    Systolic performance of the single ventricle, exercise capacity, and endothelial function in pediatric Fontan patients.
    Am Heart J. 2025;290:58-68.
    PubMed     Abstract available
    
    
    
40. WEI C, Sharma P, Paranjpe I, Heidenreich PA, et al
    Balancing cost and care: Analyzing commercial pricing for TAVR and SAVR.
    Am Heart J. 2025;290:1-5.
    PubMed     Abstract available
    
    
    November 2025
41. SHAN J, Gao J, Chen Y, Ji H, et al
    Efficacy and Safety of Postoperative Autologous Blood Transfusion in Cardiac Surgery (RESCUE): Rationale, Design, and Study Protocol of a Multicenter Randomized Controlled Trial.
    Am Heart J. 2025 Nov 27:107313. doi: 10.1016/j.ahj.2025.107313.
    PubMed     Abstract available
    
    
    
42. MAGOD BL, Hughes ZH, Manjunath A, Wu T, et al
    Incidence and risk factors for malignancy after heart transplantation- Analysis of the UNOS Registry.
    Am Heart J. 2025 Nov 21:107308. doi: 10.1016/j.ahj.2025.107308.
    PubMed     Abstract available
    
    
    
43. LI J, Wang ZY, Yan J, Li WH, et al
    Prospective, multicenter, randomized controlled study on the efficacy and safety of intravascular ultrasound-guided drug-coated balloon for de novo small-vessel coronary lesions: Design and rationale of the DCB-IVUS trial.
    Am Heart J. 2025 Nov 18:107307. doi: 10.1016/j.ahj.2025.107307.
    PubMed     Abstract available
    
    
    
44. VAN DEN ENDEN AJM, van den Dorpel MMP, Mondellini GM, Mattace-Raso AM, et al
    Immediate changes in Left Ventricular Cardiac Mechanics following Transcatheter Aortic Valve Replacement for Severe Aortic Stenosis - an In-Vivo Pressure-Volume Analysis study.
    Am Heart J. 2025 Nov 13:107302. doi: 10.1016/j.ahj.2025.107302.
    PubMed     Abstract available
    
    
    
45. MONTALESCOT G, Bolognese L, Bartus S, Cequier-Fillat A, et al
    Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: Design of the AMUNDSEN Trial.
    Am Heart J. 2025 Nov 3:107295. doi: 10.1016/j.ahj.2025.107295.
    PubMed     Abstract available
    
    
    
46. TOBE A, van Royen N, Amat-Santos IJ, Hudec M, et al
    Win ratio analysis of the LANDMARK trial.
    Am Heart J. 2025;289:1-5.
    PubMed     Abstract available
    
    
    October 2025
47. HEMELRIJK K, Jimenez-Diaz VA, Vilchez JP, Oteo JF, et al
    Rationale and design of REAC-TAVI 2: single antiplatelet treatment with ticagrelor versus aspirin after transcatheter aortic valve implantation.
    Am Heart J. 2025 Oct 31:107293. doi: 10.1016/j.ahj.2025.107293.
    PubMed     Abstract available
    
    
    
48. OVERDUIN DC, van Ginkel DJ, Dubois C, Lesizza P, et al
    Routine versus selective protamine administration to reduce bleeding after TAVI: Rationale and Design of the POPular ACE TAVI trial.
    Am Heart J. 2025 Oct 31:107296. doi: 10.1016/j.ahj.2025.107296.
    PubMed     Abstract available
    
    
    
49. IGLESIAS JF, Leibundgut G, Heg D, Gasparini GL, et al
    Distal versus conventional radial large-bore access for percutaneous coronary intervention of complex coronary lesions: Rationale and design of the DISCO COMPLEX randomized superiority trial.
    Am Heart J. 2025 Oct 18:107291. doi: 10.1016/j.ahj.2025.107291.
    PubMed     Abstract available
    
    
    
50. ABDELAZIZ A, Ramadan S, Hasan MT, Desouky M, et al
    Complete Revascularization in Patients with Acute Myocardial Infarction and Multivessel Disease: Pooled Analysis of Kaplan-Meier-Derived Individual-Patient-Data.
    Am Heart J. 2025 Oct 2:107284. doi: 10.1016/j.ahj.2025.107284.
    PubMed     Abstract available
    
    
    
51. KIM KS, Belley-Cote EP, Walsh M, Wang A, et al
    Left atrial appendage occlusion study III-Kidney substudy.
    Am Heart J. 2025;288:90-100.
    PubMed     Abstract available
    
    
    September 2025
52. TOMII D, Alaour B, Heg D, Okuno T, et al
    Self-Expanding Versus Balloon-Expandable Transcatheter Heart Valves in Patients with Excessive Aortic Valve Cusp Calcification.
    Am Heart J. 2025 Sep 18:S0002-8703(25)00333-3. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
53. LANDMESSER U, Skurk C, Kirchhof P, Lewalter T, et al
    Catheter-based left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding as compared to best medical therapy: Rationale and design of the prospective randomized CLOSURE-AF trial.
    Am Heart J. 2025 Sep 12:S0002-8703(25)00326-6. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
54. FEISTRITZER HJ, Jobs A, Zeymer U, Schneider S, et al
    Complete revascularization versus culprit-lesion only PCI in patients with NSTEMI and multivessel disease - Design and rationale of the randomized COMPLETE-NSTEMI trial.
    Am Heart J. 2025;287:94-106.
    PubMed     Abstract available
    
    
    August 2025
55. HOLMEN S, Manintveld O, Damman K, Braun O, et al
    DAPAgliflozin for Renal protection in Heart Transplant recipients. Rationale and design of the randomized controlled DAPARHT trial.
    Am Heart J. 2025 Aug 19:S0002-8703(25)00300-X. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
56. PARK HS, Suh CH, Ahn JM, Kang DY, et al
    Effect of Cerebral Embolic Protection Device on New Cerebral Embolism During Transcatheter Aortic Valve Replacement: A Prospective Sentinel Registry.
    Am Heart J. 2025 Aug 13:S0002-8703(25)00296-0. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    July 2025
57. JORGENSEN TH, Thyregod HGH, Blankenberg S, Leon M, et al
    The Low-Risk TAVR Trials - A Critical Appraisal of the Current Landscape.
    Am Heart J. 2025 Jul 29:S0002-8703(25)00288-1. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
58. VAKILPOUR A, Levin MG, Anyanwu EC, Denduluri S, et al
    Referral patterns and clinical outcomes in patients with severe aortic stenosis: A multicenter cohort study.
    Am Heart J. 2025 Jul 22:S0002-8703(25)00223-6. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
59. HAN M, Kang J, Kim B, Hwang D, et al
    The impact of body mass index (BMI) on antiplatelet monotherapy strategy for secondary prevention after percutaneous coronary intervention: A sub-study of the HOST-EXAM trial.
    Am Heart J. 2025 Jul 5:S0002-8703(25)00214-5. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
60. PITARO N, Nicolas J, Sartori S, Shneyderman M, et al
    Impact of Left Ventricular Function on Outcomes in Patients with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention.
    Am Heart J. 2025 Jul 1:S0002-8703(25)00203-0. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    June 2025
61. KRASNIQI L, Skovbo JS, Hallas PJ, Brandes PA, et al
    Impact of statin treatment on postoperative atrial fibrillation in surgical aortic valve replacement.
    Am Heart J. 2025 Jun 13:S0002-8703(25)00194-2. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
62. CUTLIP DE, Mehran R, Doros G, Kaplinskiy V, et al
    Prospective randomized single-blind multicenter study to assess the safety and effectiveness of the SELUTION SLR 014 drug eluting balloon in the treatment of subjects with in-stent restenosis: Rationale and design.
    Am Heart J. 2025;284:11-19.
    PubMed     Abstract available
    
    
    May 2025
63. MAINI AS, Abu-Much A, Redfors B, Wollmuth JR, et al
    Outcomes Among Patients with Coronary Bifurcation Lesions Undergoing Impella-Supported High-Risk Percutaneous Coronary Intervention.
    Am Heart J. 2025 May 22:S0002-8703(25)00176-0. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
64. WHITE HD, O'Brien SM, Boden WE, Fremes SE, et al
    Use of Coronary Artery Bypass Graft Surgery and Percutaneous Coronary Intervention and Associated Outcomes in the ISCHEMIA Trial.
    Am Heart J. 2025 May 20:S0002-8703(25)00165-6. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
65. GOLD ME, Kulkarni S, Yadalam A, Patel KJ, et al
    Cardiac Allograft Vasculopathy Mediates the Relationship Between Vitamin D Deficiency and Cardiovascular Mortality Following Heart Transplantation.
    Am Heart J. 2025 May 16:S0002-8703(25)00166-8. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
66. MESSINGER MC, Ashburn NP, Chait JS, Snavely AC, et al
    Risk of delayed percutaneous coronary intervention for STEMI in the Southeast United States.
    Am Heart J. 2025 May 13:S0002-8703(25)00157-7. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
67. KANDZARI DE, Latib A, Mylotte D, Ali ZA, et al
    Rationale and design of the prevail global trial program evaluating the prevail drug-coated balloon in patients with in-stent restenosis and de novo small vessel disease.
    Am Heart J. 2025;283:26-36.
    PubMed     Abstract available
    
    
    April 2025
68. JIANG Z, Chang S, Tao L, Luo J, et al
    The randomized controlled trial to compare temporary permanent pacemaker versus temporary pacemaker in patients with conduction block after transcatheter aortic valve replacement: rationale and design of the RECOVER trial: Randomized trial for Tempora
    Am Heart J. 2025 Apr 19:S0002-8703(25)00135-8. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
69. GOSVIG K, Goller J, Hansson NH, Brandes A, et al
    Rationale and design of the Anticoagulant Therapy after Left Atrial Appendage Closure (ATLAAC) Trial.
    Am Heart J. 2025 Apr 15:S0002-8703(25)00131-0. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
70. HAKEEM A, Ali Shah J, Kumar R, Khan K, et al
    Rationale and Design of the TADCLOT Trial: A Double Blind Randomized Controlled Trial Comparing Twice a Day Clopidogrel vs. Ticagrelor in Reducing Major Cardiac Events in Patients with Acute STEMI Undergoing Primary Percutaneous Coronary Intervention.
    Am Heart J. 2025 Apr 12:S0002-8703(25)00103-6. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
71. SOMSEN YBO, de Winter RW, Wu J, Hoek R, et al
    Design and rationale of the drug-coated balloon coronary angioplasty versus stenting for treatment of disease adjacent to a chronic total occlusion (Co-CTO) trial.
    Am Heart J. 2025 Apr 7:S0002-8703(25)00105-X. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
72. HORN N, Gartner L, Rastan AJ, Andrasi TB, et al
    Effects of a preoperative psychological expectation-focused intervention in patients undergoing valvular surgery - the randomized controlled ValvEx (valve patients' expectations) study.
    Am Heart J. 2025;282:156-169.
    PubMed     Abstract available
    
    
    
73. HSU AR, Karnakoti S, Abdelhalim AT, Miranda WR, et al
    Incidence and outcomes of prosthetic valve endocarditis in adults with congenital heart disease.
    Am Heart J. 2025;282:125-133.
    PubMed     Abstract available
    
    
    February 2025
74. AUER J, Lamm G
    High-risk features and probability of ischemic and bleeding events after percutaneous coronary intervention.
    Am Heart J. 2025 Feb 26:S0002-8703(25)00058-4. doi: 10.1016/j.ahj.2025.
    PubMed    
    
    
    
75. ANDO T, Nazif T, Briasoulis A, Afonso L, et al
    Clinical Outcomes of Direct Oral Anticoagulant Versus Warfarin After Transcatheter Aortic Valve Replacement: From the STS/ACC TVT Registry.
    Am Heart J. 2025 Feb 26:S0002-8703(25)00057-2. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
76. ERRIQUEZ A, Colaiori I, Hakeem A, Guiducci V, et al
    Functional Coronary Angiography to Indicate and Guide Revascularization in STEMI Patients with Multivessel Disease: Rationale and Design of the AIR-STEMI trial: Functional coronary angiography in STEMI patients.
    Am Heart J. 2025 Feb 19:S0002-8703(25)00042-0. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
77. JORGENSEN TH, Thyregod HGH, Savontaus M, Bleie O, et al
    Transcatheter or Surgical Aortic Valve Replacement in patients with Severe Aortic Stenosis Aged 70 Years or Younger - a NOTION-2 sub-study.
    Am Heart J. 2025 Feb 12:S0002-8703(25)00034-1. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
78. GAO XF, Kan J, Wu HY, Chen J, et al
    Intravascular Imaging-guided versus Angiography-guided Percutaneous Coronary Intervention in Patients with Diabetes Mellitus: Rationale and design of an International, Multicenter, Randomized IVI-DIABETES Trial.
    Am Heart J. 2025 Feb 4:S0002-8703(25)00017-1. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
79. WANG G, Zhang R, Chen SL, Wang J, et al
    Targeted Therapy with a Localized abluminal Groove Low-Dose Sirolimus-Eluting Bioabsorbable Polymer Coronary Stent in Chronic Total Occlusions: The TARGET CTO Non-Inferiority Randomized Trial.
    Am Heart J. 2025 Feb 3:S0002-8703(25)00018-3. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
80. NAKASE M, Tomii D, Maznyczka A, Heg D, et al
    Five-year outcomes with self-expanding versus balloon-expandable TAVI in patients with left ventricular systolic dysfunction.
    Am Heart J. 2025;280:18-29.
    PubMed     Abstract available
    
    
    January 2025
81. BALDI C, Maio MD, Esposito L, Bellino M, et al
    How the COAPT trial affected the selection of patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge repair: insights from the GIOTTO Registry.
    Am Heart J. 2025 Jan 27:S0002-8703(25)00011-0. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
82. EFTEKHARI A, Christiansen EH, Lassen JF, Raungaard B, et al
    Randomized comparison of the combined Sirolimus eluting and endothelial progenitor cell Combo(TM) stent vs. Biolimus eluting absorbable polymer coated BioMatrix Alpha(TM) stent in patients undergoing percutaneous coronary intervention. Rationale and s
    Am Heart J. 2025 Jan 25:S0002-8703(25)00013-4. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
83. VELDTMAN GR, Abualsaud A, Cohen S, Ordonez MV, et al
    Fontan circulation and systemic disease - a retrospective cohort analysis over 35 years of follow-up.
    Am Heart J. 2025;279:40-49.
    PubMed     Abstract available
    
    
    December 2024
84. CASSESE S, Simonetti F, Covarrubias HAA, Janisch M, et al
    Intracoronary Stenting and Additional Results Achieved by ShockWAVE Coronary Lithotripsy: Design and Rationale of ISAR-WAVE Trial.
    Am Heart J. 2024 Dec 20:S0002-8703(24)00337-5. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
85. POLLACK LM, Chang A, Thompson MP, Keteyian SJ, et al
    Hospital-level variation in cardiac rehabilitation metrics.
    Am Heart J. 2024 Dec 13:S0002-8703(24)00333-8. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
86. AARTS HM, Hemelrijk KI, Broeze GM, van Ginkel DJ, et al
    Deferral of routine percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation: rationale and design of the PRO-TAVI trial: the PRO-TAVI trial: rationale and design.
    Am Heart J. 2024 Dec 12:S0002-8703(24)00332-6. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    November 2024
87. REDDY KP, Shultz K, Eberly LA, Khatana SAM, et al
    Contribution margins and utilization of transcatheter aortic valve replacement versus surgical aortic valve replacement in the Medicare population.
    Am Heart J. 2024 Nov 27:S0002-8703(24)00302-8. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
88. ABRAHAM B, Suppah M, Farina J, Botros M, et al
    Impact of Moderate or Severe Mitral and Tricuspid Valves Regurgitation after Transcatheter Aortic Valve Replacement.
    Am Heart J. 2024 Nov 12:S0002-8703(24)00295-3. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
89. IANNOPOLLO G, Cocco M, Leone A, Sacca S, et al
    TRanscatheter Aortic-Valve Implantation with or without on-site Cardiac Surgery: the TRACS trial: TAVI in centers without on-site cardiac surgery.
    Am Heart J. 2024 Nov 4:S0002-8703(24)00281-3. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    October 2024
90. BARONE-ROCHETTE G, Vanzetto G, Danchin N, Steg PG, et al
    Rationale and design of the multicentric randomized EVAOLD trial: evaluation of a strategy guided by imaging versus routine invasive strategy in elderly patients with ischemia.
    Am Heart J. 2024 Oct 22:S0002-8703(24)00274-6. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
91. WHITLOCK RP, McCarthy PM, Gerdisch MW, Ramlawi B, et al
    The left atrial appendage exclusion for prophylactic stroke reduction (leaaps) trial: rationale and design.
    Am Heart J. 2024 Oct 10:S0002-8703(24)00268-0. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
92. THURAIAIYAH J, Jorgensen TH, Jensen JM, Fuchs A, et al
    Prospective study on the impact of different anti-thrombotic therapies on subclinical leaflet thickening and its temporal dynamics in transcatheter aortic valves - The NOTION-4 trial: Anti-thrombotic therapy and TAV-HALT.
    Am Heart J. 2024 Oct 5:S0002-8703(24)00264-3. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    September 2024
93. DE COCK E, Kautbally S, Timmermans F, Bogaerts K, et al
    Low-dose colchicine for the prevention of cardiovascular events after percutaneous coronary intervention: rationale and design of the COL BE PCI trial: Short title: Rationale and design of the COL BE PCI trial.
    Am Heart J. 2024 Sep 2:S0002-8703(24)00225-4. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
94. GATTI G, Fiore A, Ismail M, Dralov A, et al
    Prediction of 30-day mortality after surgery for infective endocarditis using risk scores: Insights from a European multicenter comparative validation study.
    Am Heart J. 2024;275:108-118.
    PubMed     Abstract available
    
    
    August 2024
95. DISMORR M, Granbom-Koski M, Ellfors E, Ruck A, et al
    Sex differences and long-term clinical outcomes after transcatheter aortic valve replacement: a SWEDEHEART study.
    Am Heart J. 2024 Aug 9:S0002-8703(24)00185-6. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
96. STAHLI BE, Linke A, Westermann D, Van Mieghem NM, et al
    A Randomized Comparison of the Treatment Sequence of Percutaneous Coronary Intervention and Transcatheter Aortic Valve Implantation: Rationale and Design of the TAVI PCI Trial.
    Am Heart J. 2024 Aug 7:S0002-8703(24)00184-4. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
97. MEDINA CK, Barnes SG, Felker GM, Mentz RJ, et al
    Severe obesity among patients with left ventricular assist devices.
    Am Heart J. 2024;274:130-133.
    PubMed     Abstract available
    
    
    
98. TERKELSEN CJ, Thim T, Freeman P, Dahl JS, et al
    Randomized comparison of TAVI valves: The Compare-TAVI trial.
    Am Heart J. 2024;274:84-94.
    PubMed     Abstract available
    
    
    
99. DUARTE VE, Yamamura K, Economy KE, Graf JA, et al
    The effects of pregnancy in subjects with repaired tetralogy of Fallot.
    Am Heart J. 2024;274:95-101.
    PubMed     Abstract available
    
    
    July 2024
100. BUTT JH, Yafasova A, Thein D, Begun X, et al
     Burden of Hospitalization During the First Year Following Transcatheter and Surgical Aortic Valve Replacement.
     Am Heart J. 2024 Jul 29:S0002-8703(24)00180-7. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
101. ERBAY A, Penzel L, Abdelwahed YS, Heuberger A, et al
     Prognostic impact of quantitative flow ratio (QFR)-consistent complete revascularization in patients with myocardial infarction and multivessel coronary artery disease.
     Am Heart J. 2024 Jul 19:S0002-8703(24)00177-7. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
102. ELLFORS E, Dismorr M, Ruck A, Settergren M, et al
     Predicted prosthesis-patient mismatch and long-term clinical outcomes after transcatheter aortic valve replacement: a SWEDEHEART study.
     Am Heart J. 2024 Jul 18:S0002-8703(24)00175-3. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
103. PERSITS I, Mirzai S, Sarnaik KS, Volk MC, et al
     Sarcopenia and Frailty in Patients Undergoing Transcatheter Aortic Valve Replacement.
     Am Heart J. 2024 Jul 18:S0002-8703(24)00173-X. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
104. POLSINELLI VB, Koczo A, Johnson AE, Elkayam U, et al
     Race, Hypertensive Disorders of Pregnancy and Outcomes in Peripartum Cardiomyopathy.
     Am Heart J. 2024 Jul 10:S0002-8703(24)00168-6. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
105. YANG Y, Chu TC, Suthar D, Beshish AG, et al
     Association of patient-level characteristics with long-term outcomes after Fontan palliation: Rationale, design, and baseline characteristics of the Pediatric Cardiac Care Consortium Fontan cohort study.
     Am Heart J. 2024;273:111-120.
     PubMed     Abstract available
     
     
     June 2024
106. ABOU-KARAM R, Tanguturi V, Cheng F, Elmariah S, et al
     Trial Designs A44002PZS Electronic Physician Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis: Rationale, design, and methods of the randomized controlled DETECT AS Trial.
     Am Heart J. 2024 Jun 29:S0002-8703(24)00163-7. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
107. WU ZM, Kan J, Ye F, You W, et al
     PCSK9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Randomized, Double- Blind, Placebo-Controlled, Multicenter SHAWN Study.
     Am Heart J. 2024 Jun 26:S0002-8703(24)00157-1. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
108. MIYAWAKI N, Ishizu K, Shirai S, Miyahara K, et al
     Impact of the Clinical Frailty Scale on Long-term Outcomes After Transcatheter Aortic Valve Implantation.
     Am Heart J. 2024 Jun 12:S0002-8703(24)00139-X. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
109. BRUNO F, Rampone JM, Islas F, Gorla R, et al
     Echocardiographic and clinical features of patients developing prosthesis-patient mismatch after TAVR: insights from the Recovery TAVR registry.
     Am Heart J. 2024 Jun 3:S0002-8703(24)00137-6. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     May 2024
110. RICHARDSON C, Gilbert T, Aslam S, Brookes CL, et al
     Rationale and design of the Early valve replacement in severe ASYmptomatic Aortic Stenosis Trial.
     Am Heart J. 2024 May 29:S0002-8703(24)00128-5. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
111. LUPU L, Haberman D, Chitturi KR, Wermers JP, et al
     Overview of 2024 FDA Advisory Panel Meeting on the TriClip Transcatheter Tricuspid Valve Repair System.
     Am Heart J. 2024 May 29:S0002-8703(24)00126-1. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
112. KIM Y, Park H, Yoon HJ, Suh J, et al
     Fully Automated Quantitative Coronary Angiography Versus Optical Coherence Tomography Guidance for Coronary Stent Implantation (FLASH): Study Protocol for a Randomized Controlled Non-Inferiority Trial.
     Am Heart J. 2024 May 7:S0002-8703(24)00119-4. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
113. ZHANG F, Tian M, Wang X, Zhang H, et al
     Rationale and design of a Single-center Randomized Trial to Compare the Graft Patency between the Radial Artery and the No-touch Saphenous Vein in Coronary Artery Bypass Grafting Surgery (GRAFT-CAB Study).
     Am Heart J. 2024 May 4:S0002-8703(24)00117-0. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
114. LEMLEY BA, Okunowo O, Ampah SB, Wu L, et al
     Effect of patient factors, center, and era on Fontan timing: An observational study using the Pediatric Health Information Systems Database.
     Am Heart J. 2024;271:156-163.
     PubMed     Abstract available
     
     
     
115. GUO Y, Liu X, Li R, Ng S, et al
     Comparison of Down Sizing Strategy (HANGZHOU Solution) and Standard Annulus Sizing Strategy in type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement: Rationale and design of a randomized clinical trial.
     Am Heart J. 2024 May 1:S0002-8703(24)00098-X. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     April 2024
116. KIM MC, Ahn JH, Hyun DY, Lim Y, et al
     Timing of fractional flow reserve-guided complete revascularization in patients with ST-segment elevation myocardial infarction with multivessel disease: Rationale and design of the OPTION-STEMI trial.
     Am Heart J. 2024 Apr 17:S0002-8703(24)00078-4. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
117. ETIWY M, Flannery LD, Li SX, Morrison FJ, et al
     Examining Lack of Referrals to Heart Valve Specialists as Mechanisms of Potential Underutilization of Aortic Valve Replacement.
     Am Heart J. 2024 Apr 13:S0002-8703(24)00093-0. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     March 2024
118. GUINOT PG, Desebbe O, Besch G, Guerci P, et al
     Prospective randomized double-blind study to evaluate the superiority of Vasopressin versus Norepinephrine in the management of the patient at renal risk undergoing cardiac surgery with cardiopulmonary bypass (NOVACC trial).
     Am Heart J. 2024 Mar 14:S0002-8703(24)00068-1. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
119. KRUCOFF M, Spirito A, Baber U, Sartori S, et al
     Ticagrelor With or Without Aspirin Following Percutaneous Coronary Intervention in High-Risk Patients With Concomitant Peripheral Artery Disease: a subgroup analysis of the TWILIGHT randomized clinical trial.
     Am Heart J. 2024 Mar 6:S0002-8703(24)00053-X. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
120. DOU D, Yuan S, Jia Y, Wang Y, et al
     The protocol of enhanced recovery after cardiac surgery in adult patients: a stepped wedge cluster randomized trial.
     Am Heart J. 2024 Mar 2:S0002-8703(24)00051-6. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     February 2024
121. ZHANG J, Kong XQ, Gao XF, Chen J, et al
     Transfemoral transcatheter aortic valve replacement with VitaFlow(TM) valve for pure native aortic regurgitation in patients with high surgical risk: Rationale and design of a prospective, multicenter, and randomized SEASON-AR trial.
     Am Heart J. 2024 Feb 25:S0002-8703(24)00049-8. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     January 2024
122. JAMMOUL N, Dupasquier V, Akodad M, Meunier PA, et al
     Long-term follow-up of balloon-expandable valves according to the implantation strategy: insight from the DIRECTAVI trial.
     Am Heart J. 2024 Jan 20:S0002-8703(24)00014-0. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     September 2023
123. ATALLAH J, Chiha T, Chen C, Siller-Matula JM, et al
     Clinical outcomes associated with type II myocardial infarction caused by bleeding.
     Am Heart J. 2023;263:85-92.
     PubMed     Abstract available
     
     
     August 2023
124. DODGSON CAS, Beitnes JO, Klove SF, Herstad J, et al
     An investigator-sponsored pragmatic randomised controlled trial of AntiCoagulation versus AcetylSalicylic Acid after Transcatheter Aortic Valve Implantation - Rationale and design of ACASA-TAVI: Blinded outcome adjudication.
     Am Heart J. 2023 Aug 25:S0002-8703(23)00208-9. doi: 10.1016/j.ahj.2023.
     PubMed     Abstract available
     
     
     July 2023
125. KALMUCKI P, Lipiecki J, Witte KK, Goldberg SL, et al
     Percutaneous mitral annuloplasty with the Carillon device: outcomes in proportionate and disproportionate functional mitral regurgitation.
     Am Heart J. 2023 Jul 27:S0002-8703(23)00181-3. doi: 10.1016/j.ahj.2023.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Thoracic Surgery is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum